Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 14, 2026
Why Is HeartFlow (HTFL) Stock Up +26.8% Today?

Why Is HeartFlow (HTFL) Stock Up +26.8% Today?

Key Takeaways

  • HeartFlow shares surged approximately 26.8% in early trading Thursday, changing hands around $39.32 versus Wednesday’s close of $31.01.
  • The move was an earnings-driven rally after second-quarter results beat expectations and the company raised its full-year outlook.
  • Plaque Analysis was the standout growth driver, with revenue of $7.8 million coming in about $4 million above internal expectations.
  • Analysts raised price targets following the report, reinforcing bullish sentiment.
  • The stock was trading within roughly 5% of its 52-week high of $41.22.
  • Traders are watching Plaque adoption, second-half execution, and upcoming clinical data readouts.

Opening Summary

HeartFlow, Inc. (HTFL) is a medical technology company that provides AI-powered, non-invasive solutions for diagnosing and managing coronary artery disease. Its shares rallied sharply in early trading Thursday, rising $8.31, or about 26.8%, to $39.32, compared with a prior closing price of $31.01 on Wednesday. The move extended a strong pre-market surge and reflected an enthusiastic market reaction to second-quarter 2026 results released after Wednesday’s close, which beat revenue expectations and included raised full-year guidance.

Q2 Earnings Beat and Raised Full-Year Outlook

HeartFlow (HTFL) reported second-quarter revenue of $64.1 million, up 48% year over year and above the consensus estimate of about $56.6 million. U.S. revenue rose 51% to $59.6 million, while international and other revenue reached $4.5 million. The company’s non-GAAP net loss narrowed to $5.8 million, or $0.07 per share, from $17.6 million, or $2.79 per share, in the same period a year earlier.

Management also raised its full-year 2026 revenue guidance to a range of $246 million to $250 million, implying growth of 40% to 42%, up from a prior outlook of $228 million to $232 million. The company increased its full-year non-GAAP gross margin guidance to approximately 82% and reiterated its target of reaching cash flow profitability by mid-2028.

Plaque Momentum and Margin Expansion

A key driver of the quarter was HeartFlow’s Plaque Analysis business. Plaque revenue of $7.8 million represented about 12% of total revenue and came in roughly $4 million above the company’s expectations. Management said new account activations were ahead of plan and that coverage had reached about 78% of insured lives. The company raised its full-year Plaque revenue outlook to $29 million to $31 million and now expects approximately 1,250 activated Plaque accounts by year-end.

The core FFRCT business also contributed, with U.S. FFRCT revenue growing about 32% during the quarter. Gross margin expanded to 83.3%, up 770 basis points from 75.6% a year earlier, supported by volume leverage, AI-driven efficiencies, and a higher mix of high-margin Plaque revenue.

Analyst Price-Target Increases Reinforce the Move

The earnings-driven stock move was amplified by a wave of analyst activity. Stifel raised its price target on HTFL to $45 from $40 and maintained a Buy rating, citing strength in both the Plaque and FFRCT businesses. J.P. Morgan maintained a Buy rating with a $45 price target, while Wells Fargo maintained a Buy rating with a $39 target. The analyst response reinforced the view that HeartFlow’s accelerating revenue growth and improving margins are gaining credibility on Wall Street.

Market Context and Trading Activity

The rally appeared to be company-specific rather than driven by broad market or sector action. Shares jumped more than 20% in pre-market trading and extended those gains after the opening bell, moving from Wednesday’s close of $31.01 to around $39.32 by mid-morning Thursday. Wednesday’s regular-session volume of roughly 1.07 million shares was more than double the prior nine-session average of about 425,000 shares, indicating elevated investor interest even before the earnings announcement. The stock also traded near the upper end of its 52-week range, approaching its 52-week high of $41.22.

What Comes Next for HTFL

Investors will now focus on whether HTFL can sustain its Plaque adoption momentum and deliver on its raised revenue and margin guidance through the second half of 2026. Key catalysts include continued account activations, reimbursement developments, the DECIDE one-year outcomes expected in the fourth quarter, and broader evidence supporting expansion into the asymptomatic patient market. Risks include an ongoing competitive and regulatory environment, persistent GAAP losses, and a premium valuation that leaves the shares sensitive to any execution shortfall.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing traders to explore automated approaches matched to different market environments. Readers interested in AI-driven market analysis can visit the page to review the latest top-performing strategies.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HTFL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


HTFL's Stochastic Oscillator is staying in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

HTFL moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HTFL crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

The 50-day moving average for HTFL moved above the 200-day moving average on August 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +5.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where HTFL advanced for three days, in 63 of 70 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

HTFL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 29 of 41 cases where HTFL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.

Bearish Trend Analysis

The 10-day RSI Indicator for HTFL moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In 5 of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HTFL as a result. In 17 of 23 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for HTFL turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 9 similar instances when the indicator turned negative. In 9 of the 9 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTFL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HTFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.144) is normal, around the industry mean (7.129). HTFL has a moderately low P/E Ratio (0.000) as compared to the industry average of (44.308). HTFL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.486). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. HTFL's P/S Ratio (18.587) is slightly higher than the industry average of (5.914).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.72B. The market cap for tickers in the group ranges from 708 to 42.25B. VEEV holds the highest valuation in this group at 42.25B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -3%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 19%. ONMD experienced the highest price growth at 13%, while WAY experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -33% and the average quarterly volume growth was -46%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 75
Price Growth Rating: 54
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -29 (-100 ... +100)
View a ticker or compare two or three
HTFL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Profile
Details
Industry
N/A
Address
331 East Evelyn Avenue
Phone
+1 650 241-1221
Employees
843
Web
https://www.heartflow.com
Interact to see
Advertisement
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.
CRCL surged +8.66% on Monday, March 9, 2026, rising from a prior close of $101.94 to trade at $110.77 intraday. The primary catalyst is a landmark stablecoin milestone: Circle's USDC overtook Tether as the dominant stablecoin by transfer volume, accounting for approximately 70% of all stablecoin transfer activity as total stablecoin transfers hit $1.8 trillion in February.
Carnival Corporation (CCL) shares fell approximately -7.60% in Monday's session, dropping from a Friday close of $25.79 to around $23.83. The primary catalyst is a broad market sell-off driven by intensifying recession fears, with the S&P 500 and consumer discretionary names bearing the brunt of the pressure.
Shares of Bloom Energy (BE) are surging approximately +10.30% in Monday's session, rebounding sharply from a steep -15.50% selloff on Friday, March 6, 2026. Friday's decline was triggered by an Oracle-OpenAI data center project update that spooked energy infrastructure investors; Monday's move reflects aggressive dip-buying and a sentiment reset.
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.
Shares of ARQ plunged approximately 27.50% in premarket trading on March 10, 2026, from a prior close of $3.20 to roughly $2.32. The primary catalyst was a deeply disappointing Q4 2025 earnings report, which revealed a net loss of $50.0 million for the quarter versus a net loss of $1.3 million in Q4 2024.
RAIL shares fell approximately 15% in premarket trading on March 10, 2026, following a steep after-hours reaction to disappointing Q4 2025 earnings results released after the close on March 9. The primary catalyst was a significant revenue miss: Q4 revenue came in at $125.6 million, well below consensus estimates near $144–$160 million, representing an 8.8% year-over-year decline.
ZVRA shares surged approximately +17.86% on March 10, 2026, driven by a blockbuster Q4 and full-year 2025 earnings report released before the market open. Primary catalyst: Q4 2025 EPS of $0.19 crushed the consensus estimate of $0.05 — a 280% beat — while revenue of $34.1 million exceeded forecasts by 21.57%.
LITE surged +14.73% on Monday, March 9, 2026, closing at $640.69 versus a prior close of $558.44 on March 6. The primary catalyst was the landmark $2 billion strategic investment by NVIDIA announced March 2, with the market continuing to price in its full implications following a brief post-announcement pullback.
Shares of BNTX fell approximately 22% on Tuesday, March 10, 2026, following a dual shock of disappointing full-year guidance and a surprise leadership upheaval. The primary catalyst was BioNTech's Q4 2025 earnings report, which included a 2026 revenue outlook of €2.0–€2.3 billion — well below analyst consensus and signaling continued pressure from declining COVID-19 vaccine demand.
CNC shares fell approximately 10% during Tuesday's session, extending a prolonged selloff in the managed care sector. The primary catalyst is intensifying investor concern over federal Medicaid and ACA funding cuts tied to the "One Big Beautiful Bill Act" (OBBBA), which threatens to shrink the government-sponsored insurance pools that Centene depends on for the majority of its revenue.
Technology recently peaked near 35% of the S&P 500 and has slipped over the last year, while Energy plus Materials remain near historically low combined weight at roughly 6%, which suggests the gap is still unusually wide.
Average daily equity purchases by retail investors on S&P 500 down days in 2026 are at the highest level on record, running about 100% above the peak intensity seen during the 2021 meme‑stock boom.
Over the past two weeks, PLTR has climbed from roughly the high‑130s to the mid‑150s, a gain of about 12–14%, with a series of strong up days between March 2 and March 6.
AVAV shares dropped approximately 10% in premarket trading on March 11, 2026, following a disappointing Q3 fiscal 2026 earnings report released after the prior session's close. Q3 revenue of $408.0 million came in far below analyst consensus of approximately $475–$488 million, representing a massive top-line miss.
KOS shares are down approximately 20% in premarket trading on March 11, 2026, having shed roughly 20.31% across the last two sessions (Tuesday close and premarket Wednesday). The primary catalyst is Kosmos Energy's announcement of a massive $185.25 million public equity offering priced at $1.90 per share — a steep discount to recent trading levels.